Status:
COMPLETED
Evaluation of Copeptin in Patients With Cirrhosis and Ascites
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Cirrhotic Patients With Ascites
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Copeptin is a glycopeptide released by the post-pituitary gland. In case of decrease in blood volume or blood pressure, it is secreted in the serum in an equimolar quantity to arginine vasopressin (AV...
Detailed Description
The investigators wish to include prospectively 100 cirrhotic patients with ascites requiring prolonged hospitalization in the Hepato-gastroenterology departments of the Besançon, Nancy and Reims hosp...
Eligibility Criteria
Inclusion
- Man or woman
- Age between 18 and 80 years
- Acute decompensation of cirrhosis with occurrence of ascites
- Hospitalisationfor a complication of cirrhosis (first occurrence of ascites or recurrent ascites requiring hospitalization, gastrointestinal bleeding, hepatic encephalopathy, etc..)
- Patients participating to Ca-DRISLA study
- Information and Consent form signed
Exclusion
- Pregnant or breastfeeding woman
- Age minor to 18 years
- Age major to 80 years
- Adult under protection law
- outpatients hospitalized for paracentesis
- ascites not related to portal hypertension (pancreatic ascites, peritoneal carcinosis…) Patients with hepatocellular carcinoma could be included
Key Trial Info
Start Date :
May 9 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 7 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03318601
Start Date
May 9 2016
End Date
March 7 2022
Last Update
January 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Besançon
Besançon, France, 25030